A Naturalistic Study of Ketamine for Treatment Resistant Mood Disorders

This prospective naturalistic study evaluates safety, tolerability, and effectiveness of repeated, individually tailored ketamine administered IV, intranasally and orally in inpatients with treatment‑resistant major depressive disorder and bipolar depression.

Dosing regimens include slow IV infusions (0.5 mg/kg over 40 minutes) and twice-weekly intranasal and oral administrations (oral 2.0–2.5 mg/kg), delivered over a 4‑week period; outcomes include clinical response, safety and tolerability measures.